On Monday, Owens & Minor Inc. (NYSE:OMI) reported adjusted EPS of $0.45 for the fourth quarter of 2024, down from $0.69 a year ago but beating the consensus of $0.52.
The company reported sales of $2.70 billion, up 1.5% year-over-year, beating the consensus of $2.69 billion.
Patient Direct revenue of $695.02 million, up 4.6% year-over-year.
Products & Healthcare Services revenue of $2 billion increased marginally by 0.5%.
Also Read: Owens & Minor Stock Dips On Mixed Q4 Preliminary Results & $310 Million Apria Goodwill Charge: Details
The company reported fourth-quarter adjusted operating income of $95.4 million, down from $110.8 million. Adjusted EBITDA fell from $169.6 million to $138.21 million.
The company says Citi is serving as Owens & Minor’s exclusive financial advisor regarding the potential sale of the Products & Healthcare Services segment.
Owens & Minor CEO Edward Pesicka said the company continues to leverage its footprint and broad product offering to support home-based care for millions of patients with chronic conditions.
“These capabilities, combined with positive demographic trends and expanding home treatment options, leaves us very bullish on the future of this business,” Pesicka said.
Owens & Minor also repaid $647 million of debt over the last two years which helped with the company’s acquisition of Rotech, he added.
Pesicka added, "Our commitment to directing capital toward the higher growth and higher margin Patient Direct segment has been increasingly evident in recent years and is consistent with our strategy. As a logical next step, we have been actively engaged in robust discussions regarding the potential sale of our Products & Healthcare Services segment."
Share Buyback: The Owens & Minor Board of Directors authorized a share repurchase program of up to $100 million over the next 24 months.
Guidance: Owens & Minor expects 2025 Revenues of $10.85 billion-$11.15 billion and adjusted EPS of $1.60-$1.85 versus consensus of $10.97 billion and $1.79, respectively.
The healthcare logistics company expects adjusted EBITDA for 2025 to be $560 million to $590 million.
Price Action: OMI stock is up 9.29% at $7.53 during the premarket session at the last check Friday.
Read Next:
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。